Comparing Accuracy Findings from the proPSMA Study for PSMA PET/CT and Conventional Imaging

Declan Murphy discusses the accuracy findings from the proPSMA study presented at the 2020 SUO Meeting.

Professor Declan Murphy of the Peter MacCallum Cancer Centre broke down the recent accuracy findings in an interview with CancerNetwork on his research for the proPSMA study to treat patients with prostate cancer.


So, the primary end point of proPSMA was accuracy. We wanted to compare this novel imaging with PSMA PET/CT with conventional imaging. One of the first comments I’ll make I suppose is that we know conventional imaging does quite poorly in staging these newly diagnosed high-risk prostate cancers. All too often conventional imaging with CT and bone scan or even MRI scan will fail to detect small volume disease outside the prostate. Patients will go on and have local treatment to the prostate with surgery or radiation but have a high recurrence rate. You know, 40-50% of patients will have biochemical recurrence, and really part of that failure is that the patients were not correctly staged in the first instance because conventional imaging does poorly.

So, I think that’s what the control arm of our study showed, that when we compared conventional imaging with the reference standard—so we had to define a reference standard for what the ground truth might be—we see conventional imaging is only right about 65% of the time. Whereas, when we use PSMA PET/CT, we know it’s right more than 90% of the time. So, this gives us a big delta at 27% difference in accuracy between PSMA PET/CT and conventional imaging.

Related Videos
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
Related Content